Daniel Anderson

Dr. Daniel Anderson

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2024 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
ZNZachary Nelson
Zachary Nelson
AAAbdullah Tarik Aslan
Abdullah Tarik Aslan
NBNathan P Beahm
Nathan P Beahm
MBMichelle D Blyth
Michelle D Blyth
MCMatthew Cappiello
Matthew Cappiello
ALAlfredo J. Mena Lora
Alfredo J. Mena Lora
Importance: Traditional approaches to practice guidelines frequently result in dissociation between strength of recommendation and quality of evidence. Objective: To create a clinical guideline for the diagnosis and management of urinary tract infections that addresses the gap between the evidence and recommendation strength. Evidence Review: This consensus statement and systematic review applied an approach previously established by the WikiGuidelines Group to construct collaborative clinical guidelines. In May 2023, new and existing members were solicited for questions on urinary tract infection prevention, diagnosis, and management. For each topic, literature searches were conducted up until early 2024 in any language. Evidence was reported according to the WikiGuidelines charter: clear recommendations were established only when reproducible, prospective, controlled studies provided hypothesis-confirming evidence. In the absence of such data, clinical reviews were developed discussing the available literature and associated risks and benefits of various approaches. Findings: A total of 54 members representing 12 countries reviewed 914 articles and submitted information relevant to 5 sections: prophylaxis and prevention (7 questions), diagnosis and diagnostic stewardship (7 questions), empirical treatment (3 questions), definitive treatment and antimicrobial stewardship (10 questions), and special populations and genitourinary syndromes (10 questions). Of 37 unique questions, a clear recommendation could be provided for 6 questions. In 3 of the remaining questions, a clear recommendation could only be provided for certain aspects of the question. Clinical reviews were generated for the remaining questions and aspects of questions not meeting criteria for a clear recommendation. Conclusions and Relevance: In this consensus statement that applied the WikiGuidelines method for clinical guideline development, the majority of topics relating to prevention, diagnosis, and treatment of urinary tract infections lack high-quality prospective data and clear recommendations could not be made. Randomized clinical trials are underway to address some of these gaps; however further research is of utmost importance to inform true evidence-based, rather than eminence-based practice.

14 February 2022 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
DADaniel Anderson
Daniel Anderson
BABenjamin Albrecht
Benjamin Albrecht
KJK Ashley Jones
K Ashley Jones
JJJesse T Jacob
Jesse T Jacob
Marybeth SextonMarybeth Sexton
Marybeth Sexton
SSSujit Suchindran
Sujit Suchindran
Extended-spectrum β-lactamase (ESBL)–producing Enterobacterales are frequent causes of urinary tract infections (UTIs). Severe infections caused by ESBL Enterobacterales are often treated with carbapenems, but optimal treatment for less severe infections such as UTIs is unclear. This retrospective cohort study included patients admitted to 4 hospitals in an academic healthcare system with an ESBL UTI treated with either a noncarbapenem β-lactam (NCBL) or a carbapenem for at least 48 hours from 1 April 2014 to 30 April 2018. Those who received an NCBL were compared to those receiving a carbapenem, with a primary outcome of hospital length of stay (LOS) and secondary outcomes of clinical and microbiological response, days until transition to oral therapy, rate of relapsed infection, and rate of secondary infections with a multidrug-resistant organism. Characteristics were similar among patients who received carbapenems (n = 321) and NCBLs (n = 171). There was no difference in LOS for the NCBL group compared to the carbapenem group (13 days vs 15 days, P = .66). The NCBL group had higher rates of microbiologic eradication (98% vs 92%, P = .002), shorter time to transition to oral therapy (5 days vs 9 days, P < .001), shorter overall durations of therapy (7 days vs 10 days, P < .001), and lower rates of relapsed infections (5% vs 42%, P = .0003). Patients treated with NCBLs had similar LOS, higher rates of culture clearance, and shorter durations of antibiotic therapy compared to patients treated with carbapenems, suggesting that treatment for ESBL UTIs should not be selected solely based on phenotypic resistance.

17 June 2024 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
CLCarly Loudermilk
Carly Loudermilk
JEJoshua Eudy
Joshua Eudy
SAStephanie Albrecht
Stephanie Albrecht
CSCara N. Slaton
Cara N. Slaton
SSStefanie Stramel
Stefanie Stramel
DADaniel Anderson
Daniel Anderson
Background: Intravenous (IV) antibiotics have historically been considered standard of care for treatment of bloodstream infections (BSIs). Recent literature has shown sequential oral (PO) therapy to be noninferior to IV antibiotics for certain pathogens and disease states. However, a gap exists in the literature for BSI caused by Enterococcus faecalis. Objective: To compare outcomes of definitive sequential PO therapy to definitive IV therapy in patients with E faecalis BSI. Methods: Multicenter, retrospective, matched cohort study of adult patients with at least one blood culture positive for E faecalis from January 2017 to November 2022. Patients with polymicrobial BSI, concomitant infections requiring prolonged IV antibiotic therapy, those who did not receive antibiotic therapy, and those who died within 72 hours of index culture were excluded. Subjects were matched based on source of infection in a 2:1 (IV:PO) ratio. The primary outcome was a composite of all-cause mortality and treatment failure. Secondary outcomes included hospital length of stay (LOS), antibiotic duration, and 30-day readmission rate. Results: Of the 186 patients who met criteria for inclusion, there was no statistically significant difference in the primary composite outcome for PO compared to IV therapy (14.5% vs 21.8%; OR 0.53 [0.23-1.25]) or 30-day readmission (17.5% vs 29%; OR 0.53 [0.25-1.13]). Hospital LOS was significantly longer in patients receiving IV-only therapy (6 days vs 14 days; P < 0.001). Conclusion and Relevance: Sequential oral therapy for E faecalis BSI had similar outcomes compared to IV-only treatment and may be considered in eligible patients.

2 February 2026 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
DCDaniel Chastain
Daniel Chastain
DADaniel Anderson
Daniel Anderson
JEJoshua Eudy
Joshua Eudy
Andrés Henao-MartinezAndrés Henao-Martinez
Andrés Henao-Martinez
ACAshley Cluck
Ashley Cluck
Therapeutic drug monitoring (TDM) is essential for optimizing systemic antifungal therapy, particularly for agents with narrow therapeutic windows, variable pharmacokinetics (PK) or established exposure–response relationships. By enabling individualized dosing, TDM improves efficacy, reduces toxicity and helps prevent resistance. This review synthesizes current evidence and recommendations for antifungal TDM across available and emerging agents, including triazoles, flucytosine, echinocandins, amphotericin B, and novel therapies such as ibrexafungerp, olorofim and fosmanogepix. Voriconazole, posaconazole and itraconazole exhibit substantial interpatient variability and concentration-dependent toxicity, supporting routine TDM. Fluconazole is generally predictable but may warrant monitoring in critically ill patients, those on renal replacement therapy, or with central nervous system infections, though empiric dose escalation is often more practical. Isavuconazole has more stable PK, limiting TDM to select high-risk scenarios. Flucytosine requires TDM due to its narrow therapeutic index and resistance risk, particularly in renal impairment. Echinocandins are safe, but critically ill or obese patients may be underexposed, warranting empiric dose adjustments over routine TDM. Liposomal amphotericin B exhibits complex PK with plasma concentrations poorly reflecting active drug, precluding reliable TDM. Emerging antifungals lack sufficient data to support routine TDM. Despite strong justification, real-world utilization remains inconsistent, constrained by access, logistics and interpretive challenges. Expanding timely access, standardizing protocols and developing consensus-driven guidance, while using empiric dosing strategies where appropriate, are essential to ensure safe, effective and individualized antifungal therapy.

12 February 2024 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
DADaniel Anderson
Daniel Anderson
DSDivisha Sharma
Divisha Sharma
ACAaron M. Chase
Aaron M. Chase
ZSZoheb Irshad Sulaiman
Zoheb Irshad Sulaiman
AAAugust H. Anderson
August H. Anderson
JEJoshua Eudy
Joshua Eudy
Background: Short courses of antibiotics (7-10 days) are effective for uncomplicated gram-negative bloodstream infections (GN-BSI). However, prior studies have been limited to small cohorts of critically ill patients. Objective: The objective of this study was to evaluate the safety and efficacy of short courses of therapy compared with longer courses in patients admitted to the intensive care unit (ICU) with GN-BSI. Methods: Propensity-matched, retrospective cohort study of critically ill patients with GN-BSI. The primary outcome was a composite of 30-day mortality or 60-day relapse. Secondary endpoints were components of the composite, 30-day relapse, cure with or without adverse drug events (ADE), and ADEs. Regression analysis was performed to identify factors predictive of the composite outcome. Results: 225 patients were included in the propensity analysis, 145 in the long cohort and 80 in the short cohort. The primary outcome occurred in 3.8% of patients in the short group and 9.0% of patients in the long group ( P = 0.24). There was no difference in 30-day mortality (3.8% vs 5.5%, P = 0.79), 60-day relapse (0% vs 3.4%, P = 0.23), or 30-day readmission (20% vs 22.8%, P = 0.76). ADEs were more common in the long group (47.2% vs 34.1%, OR 1.7, 95% CI 1.04-2.9), primarily attributable to diarrhea. Conclusion and Relevance: In critically ill patients with GN-BSI, there were no efficacy outcome differences in patients treated with a short course of antibiotics compared with longer. However, patients in the short group were less likely to experience ADE. These findings suggest that short courses of antibiotics are effective for GN-BSI in critically ill patients.

27 June 2023 in Journal of Pharmacy Technology
Verified
Journal Article
Closed access
HLHui Lin
Hui Lin
DADaniel Anderson
Daniel Anderson
ACAmber Clemmons
Amber Clemmons
JEJoshua Eudy
Joshua Eudy
BNBrittny Nutt
Brittny Nutt
CFChristy Forehand
Christy Forehand
Background: Recent literature demonstrates support for using methicillin-resistant Staphylococcus aureus (MRSA) nasal swab polymerase chain reaction (NaPCR) screening as an antimicrobial stewardship tool aiding early de-escalation of anti-MRSA antimicrobials. However, immunocompromised patients have been underrepresented in previous studies despite increased risk of morbidity and mortality from multidrug-resistant organisms (MDRO). Objective: The purpose of this study was to determine the negative predictive value (NPV) of the MRSA NaPCR in hospitalized, immunocompromised adult patients with suspected pneumonia. Methods: A single-center, retrospective, observational review was conducted of hospitalized, immunocompromised adult patients that had an MRSA NaPCR obtained between March 1, 2020 and January 10, 2021. For inclusion, bacterial cultures must have been collected within 2 weeks after MRSA NaPCR. The primary outcome was the NPV of MRSA NaPCR in hospitalized, immunocompromised patients with suspected pneumonia. Secondary outcomes include NPV in other infections. Results: Between March 1, 2020 and January 10, 2021, 59 patients with 78 unique cultures, including 28 respiratory cultures, were included in the study. The NPV of the MRSA NaPCR for pneumonia was 91.7%. The NPV for bloodstream infections was 100% and for urinary tract infections was 100%, but interpretation of these results should be cautioned due to the small sample sizes. Conclusion: The NPV of MRSA NaPCR in pneumonia remains high in this study. The MRSA NaPCR has utility as a de-escalation tool in hospitalized, immunocompromised adult patients, but larger studies are warranted to evaluate all immunocompromised patient populations.